Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

References

• Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis (review). Cochrane Database Syst Rev 2006; Issue 2. Art No.: CD001211
   Web of Science ®Google Scholar
• Diamant JI, Hwang DG. Therapy for bacterial conjunctivitis. Ophthalmol Clin North Am 1999;12:15-20
   Google Scholar
• Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-8
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-5
   PubMed Web of Science ®Google Scholar
• Cavuoto K, Zutshi D, Karp CL, et al. Update on bacterial conjunctivitis in South Florida. Ophthalmology 2008;115:51-6
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999;106:1313-8
   PubMed Web of Science ®Google Scholar
• Morrissey I, Burnett R, Viljoen L, et al. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect 2004;49:109-14
   PubMed Web of Science ®Google Scholar
• Parmar P, Salman A, Kalavathy CM, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol 2006;141:282-6
   PubMed Web of Science ®Google Scholar
• Recchia FM, Busbee BG, Pearlman RB, et al. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Ophthalmol 2005;123:341-6
   PubMed Web of Science ®Google Scholar
• Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for new ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49 (Suppl. 2):S79-S83
   PubMed Web of Science ®Google Scholar
• Miller D, Flynn PW, Scott IU, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006;124:479-83
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 2003;121:1229-33
   PubMed Web of Science ®Google Scholar
• Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999;106:1319-23
   PubMed Web of Science ®Google Scholar
• Deramo VA, Lai JC, Fastenberg DM, Udall IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006;142:721-5
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Mirzalan G, Feiz V, Kang PC. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg 2006;32:515-18
   PubMed Web of Science ®Google Scholar
• Jhanji V, Sharma N, Satpathy G, Titiyal J. Fourth-generation fluoroquinolone-resistant bacterial keratitis. J Cataract Refract Surg 2007;33:1488-9
   PubMed Web of Science ®Google Scholar
• Brunner LS, Walsh PA, Norton SE, et al. Bactericidal activity of SS734, a novel fluoroquinolone, against pathogens associated with bacterial conjunctivitis. Clin Microbiol Infect 2007;13(Suppl 1):S476-
   PubMed Web of Science ®Google Scholar
• Brunner LS, Norton SE, Blondeau JM. In vitro activity of SS734, a novel fluoroquinolone, against pathogens associated with bacterial conjunctivitis. Clin Microbiol Infect 2007;13(Suppl 1):S475-76
   Google Scholar
• Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007;23:243-56
   PubMed Web of Science ®Google Scholar
• Bartlett JD. Ophthalmic Drug Facts, 19th edn. St. Louis, MO: Wolters Kluwer Health, 2008.
   Google Scholar
• Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991;112 (4 Suppl.):29S-33S
   PubMedGoogle Scholar
• Gross RD, Hoffman RO, Lindsay RN. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr 1997;36:435-44
   PubMed Web of Science ®Google Scholar
• Hwang DG, Schanzlin DJ, Rotberg MH, et al. and the Levofloxacin Bacterial Conjunctivitis Placebo-controlled Study Group. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003;87:1004-9
   PubMed Web of Science ®Google Scholar
• Katz HR, Andrews W, Creager D, et al. Moxifloxacin ophthalmic solution 0.5% hastens cure and eradicates the causative pathogens of bacterial conjunctivitis in pediatric and adult patients. Invest Ophthalmol Vis Sci 2003;44:E-2114
   Web of Science ®Google Scholar
• Yee RW, Tepedino M, Bernstein P, et al.; for the Gatifloxacin BID/QID Study Group. A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis. Curr Med Res Opin 2005;21:425-31
   PubMed Web of Science ®Google Scholar
• Lichtenstein SJ, Rinehart M and the Levofloxacin Bacterial Conjunctivitis Study Group. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS 2003;7:317-24
   PubMed Web of Science ®Google Scholar
• Adenis JP, Colin J, Verin P, et al. Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis. Eur J Ophthalmol 1995;5:82-7
   PubMedGoogle Scholar
• Adenis JP, Colin J, Verin P, et al. Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: a comparison with fusidic acid. Eur J Ophthalmol 1996;6:368-74
   PubMedGoogle Scholar
• Bron AJ, Leber G, Rizk SN, et al. Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br J Ophthalmol 1991;75:675-9
   PubMed Web of Science ®Google Scholar
• Friedlaender MH. Twice-a-day versus four-times-a-day ofloxacin treatment of external ocular infections. CLAO J 1998;24:48-51
   PubMedGoogle Scholar
• Gwon A for the Ofloxacin Study Group II. Ofloxacin vs tobramycin for the treatment of external ocular infection. Arch Ophthalmol 1992;110:1234-7
   PubMed Web of Science ®Google Scholar
• Gwon A for the Ofloxacin Study Group. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Br J Ophthalmol 1992;76:714-18
   PubMed Web of Science ®Google Scholar
• Power WJ, Collum LM, Easty DL, et al. Evaluation of efficacy and safety of ciprofloxacin ophthalmic solution versus chloramphenicol. Eur J Ophthalmol 1993;3:77-82
   PubMedGoogle Scholar
• Schwab IR, Friedlaender M, McCulley J, et al.; for the Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmol 2003;110:457-65
   PubMed Web of Science ®Google Scholar
• Tabbara KF, El-Sheikh HF, Islam SM, et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%. Eur J Ophthalmol 1999;9:269-75
   PubMed Web of Science ®Google Scholar
• Adenis JP, Brasseur G, Demailly P, et al. Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solutions. Eur J Ophthalmol 1996;6:287-92
   PubMedGoogle Scholar
• Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009; (in press)
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Advisory Committee Briefing Document. Available at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-00-Index.htm [Last accessed 12 February 2009]
   Google Scholar
• Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001;51:473-7
   PubMed Web of Science ®Google Scholar
• Rose PW, Harnden A, Brueggemann AB, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet 2005;366:37-43
   PubMed Web of Science ®Google Scholar
• McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microb Rev 1999;12:147-79
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Boros S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother 2007;19:146-51
   PubMed Web of Science ®Google Scholar
• Mamalis N. The increasing problem of antibiotic resistance. J Cataract Refract Surg 2007;33:1831-2
   PubMed Web of Science ®Google Scholar